Phase 2 of AP-101 in sporadic ALS and mutant SOD1-ALS met its primary safety and tolerability endpoint Clinically meaningful changes in outcome measures and stabilization of biomarkers were observed Data will be presented at upcoming scientific conferences and AL-S Pharma plans to engage...